Empros Pharma was founded in 2013 by researchers and entrepreneurs at Uppsala University together with the investor Flerie Invest. The company is developing EMP16, a pharmaceutical weight management treatment, planned to be ready for launch in 2027.
Hemsidan är byggd av Weblab
Chairman of the Board
Dr. Steiner is an investor and a life-science veteran. For more than 30 years, he has led several life-science companies across various geographies and stages of development. He has been with the venture capital firm HealthCap since 1997, serving as Venture Partner. He earned his MD and PhD degrees from Karolinska Institutet.
Mark is partner at Flerie Invest and he holds positions in several boards. He has a first degree in Industrial Studies from Nottingham Trent University and an MBA from the Open Business School. He has background in Business Development, Strategy, M&A and General Management and has worked for various pharma companies including Medeva, Celltech and UCB. More latterly, he was for sixteen years with the top five global CDMO, Recipharm where he we part of the Executive Committee with responsibility for Corporate Development. He has a successful history of M&A having led in excess of twenty-five transactions both acquiring and divesting businesses in a public and private setting.
Member of the board
Dr. Bloch Thomsen is Medical Director and Chief Medical Officer at Pfizer, Denmark. She has more than 15 years experiences from the pharmaceutical industry, of which 10 years at Novo Nordisk as VP Medical & Science. She has strong track record in the fields of obesity and diabetes and the related drug projects within Novo Nordisk (e.g. Victoza). Dr. Bloch Thomsen has an MD and PhD from the University of Aarhus.
Member of the board
Dr. Zdravkovic is Chief Medical Officer and Head of R&D at Swedish Orphan Biovitrum. He has more than 20 years of life science experience including senior positions at Novo Nordisk. He has worked in a number of therapeutic areas including diabetes and obesity and was involved in the development of Liraglutide for both the diabetes and obesity indications. Dr. Zdravkovic defended his thesis at University of Aarhus.
Chief Scientific Officier
Member of the Management team & Board
Ulf is one of the founders of Empros Pharma AB, He is an associate professor in clinical nutritution and metabolism at Uppsala University. He has a PhD in nutrition and a position at Uppsala University. His areas of expertise are mainly nutrition physiology and circadian metabolism. Ulf has been involved in several pre-clinical as well as clinical trials.